Iovance Biotherapeutics, Inc. (0JDK.L)
USD 3.56
(4.87%)
USD 3.56
(4.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -444.03 Million USD | -12.16% |
| 2022 | -395.89 Million USD | -15.67% |
| 2021 | -342.25 Million USD | -31.85% |
| 2020 | -259.58 Million USD | -31.4% |
| 2019 | -197.55 Million USD | -59.86% |
| 2018 | -123.58 Million USD | -34.23% |
| 2017 | -92.06 Million USD | -74.05% |
| 2016 | -52.89 Million USD | -91.23% |
| 2015 | -27.66 Million USD | -129.83% |
| 2014 | -12.03 Million USD | 64.44% |
| 2013 | -33.84 Million USD | -923.21% |
| 2012 | -3.3 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -112.97 Million USD | 2.92% |
| 2024 Q2 | -97.1 Million USD | 14.05% |
| 2023 Q2 | -106.52 Million USD | 0.78% |
| 2023 Q3 | -113.76 Million USD | -6.79% |
| 2023 Q4 | -116.37 Million USD | -2.3% |
| 2023 Q1 | -107.37 Million USD | -1.95% |
| 2023 FY | -444.03 Million USD | -12.16% |
| 2022 Q4 | -105.31 Million USD | -5.72% |
| 2022 Q3 | -99.61 Million USD | -0.27% |
| 2022 Q2 | -99.34 Million USD | -8.45% |
| 2022 Q1 | -91.6 Million USD | 7.78% |
| 2022 FY | -395.89 Million USD | -15.67% |
| 2021 Q4 | -99.33 Million USD | -15.34% |
| 2021 Q1 | -75.44 Million USD | -10.31% |
| 2021 Q2 | -81.35 Million USD | -7.82% |
| 2021 FY | -342.25 Million USD | -31.85% |
| 2021 Q3 | -86.12 Million USD | -5.86% |
| 2020 Q1 | -69.59 Million USD | -9.48% |
| 2020 Q3 | -58.57 Million USD | 7.06% |
| 2020 FY | -259.58 Million USD | -31.4% |
| 2020 Q4 | -68.39 Million USD | -16.78% |
| 2020 Q2 | -63.01 Million USD | 9.45% |
| 2019 Q2 | -47.55 Million USD | -28.69% |
| 2019 Q1 | -36.95 Million USD | -13.43% |
| 2019 FY | -197.55 Million USD | -59.86% |
| 2019 Q4 | -63.56 Million USD | -28.45% |
| 2019 Q3 | -49.48 Million USD | -4.07% |
| 2018 Q1 | -26.51 Million USD | -2.56% |
| 2018 Q3 | -33.83 Million USD | -10.34% |
| 2018 Q2 | -30.66 Million USD | -15.63% |
| 2018 FY | -123.58 Million USD | -34.23% |
| 2018 Q4 | -32.57 Million USD | 3.71% |
| 2017 Q1 | -20.68 Million USD | -31.85% |
| 2017 Q3 | -22.14 Million USD | 5.25% |
| 2017 Q4 | -25.85 Million USD | -16.73% |
| 2017 FY | -92.06 Million USD | -74.05% |
| 2017 Q2 | -23.37 Million USD | -13.02% |
| 2016 Q4 | -15.68 Million USD | 77.0% |
| 2016 Q1 | -6.88 Million USD | 17.66% |
| 2016 Q3 | -68.21 Million USD | -489.92% |
| 2016 FY | -52.89 Million USD | -91.23% |
| 2016 Q2 | -11.56 Million USD | -67.97% |
| 2015 Q4 | -8.35 Million USD | -9.5% |
| 2015 FY | -27.66 Million USD | -129.83% |
| 2015 Q3 | -7.63 Million USD | -19.92% |
| 2015 Q2 | -6.36 Million USD | -20.18% |
| 2015 Q1 | -5.29 Million USD | -8.86% |
| 2014 Q4 | -4.86 Million USD | -73.95% |
| 2014 FY | -12.03 Million USD | 64.44% |
| 2014 Q1 | -2.25 Million USD | 88.68% |
| 2014 Q2 | -2.11 Million USD | 6.61% |
| 2014 Q3 | -2.79 Million USD | -32.6% |
| 2013 Q1 | -1.04 Million USD | -130.19% |
| 2013 Q4 | -19.95 Million USD | -112.12% |
| 2013 Q2 | -3.42 Million USD | -227.68% |
| 2013 Q3 | -9.4 Million USD | -174.38% |
| 2013 FY | -33.84 Million USD | -923.21% |
| 2012 Q4 | 3.46 Million USD | 0.0% |
| 2012 FY | -3.3 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | -43.944% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -719.438% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -401.844% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | -26.115% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | -60.81% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -274.674% |
| Imunon, Inc. | -19.51 Million USD | -2175.365% |
| Dynavax Technologies Corporation | -6.38 Million USD | -6850.023% |
| Editas Medicine, Inc. | -153.21 Million USD | -189.805% |
| FibroGen, Inc. | -284.23 Million USD | -56.223% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -952.245% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 277.828% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 17.154% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 33841.413% |
| Verastem, Inc. | -87.36 Million USD | -408.243% |
| Zoetis Inc. | 2.34 Billion USD | 118.944% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 112.268% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -72.22% |
| Homology Medicines, Inc. | -53.74 Million USD | -726.223% |
| Nektar Therapeutics | -276.05 Million USD | -60.85% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -416.953% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -1013.991% |
| Perrigo Company plc | -12.7 Million USD | -3396.354% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -112.206% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 94.858% |
| Illumina, Inc. | -1.16 Billion USD | 61.754% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 107.407% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 132.698% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -301.629% |
| Waters Corporation | 642.23 Million USD | 169.139% |
| Biogen Inc. | 1.16 Billion USD | 138.243% |
| Evolus, Inc. | -61.68 Million USD | -619.846% |
| Adicet Bio, Inc. | -142.65 Million USD | -211.26% |
| bluebird bio, Inc. | -211.91 Million USD | -109.537% |
| Geron Corporation | -184.12 Million USD | -141.158% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | -0.862% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -192.931% |
| Myriad Genetics, Inc. | -112 Million USD | -296.462% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 7.721% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 156.294% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -895.525% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 364.867% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 111.231% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 135.809% |
| OPKO Health, Inc. | -188.86 Million USD | -135.111% |
| Exelixis, Inc. | 207.76 Million USD | 313.721% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 518.35% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -834.716% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -85.605% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | -21.227% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 257.687% |
| Blueprint Medicines Corporation | -506.98 Million USD | 12.416% |
| Insmed Incorporated | -749.56 Million USD | 40.761% |
| TG Therapeutics, Inc. | 12.67 Million USD | 3604.08% |
| Incyte Corporation | 597.59 Million USD | 174.304% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 41.612% |